Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)

Trial Details

NCT ID

NCT06022757

Phase

PHASE1 / PHASE2

Sponsor

Evopoint Biosciences Inc.

Status

RECRUITING

Cancer Type

Adenocarcinoma Lung Cancer

Interventions

• XNW5004
• KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection

Locations (sample)

• Guangzhou, Guodong Province, China|23.11667,113.25

Key Eligibility Criteria

• Sign informed consent form prior to the commencement of any research activity/procedure.
• Cohort 3 (mCRPC cohort) is male-only, and no gender restrictions for other cohorts.
• Subjects with advanced solid tumors who meet one of the following requirements can be enrolled in the study. No cohorts planned for the Phase Ib st…
• Cohort: 1 Histologically or cytologically confirmed recurrent or metastatic head and neck squamous cell carcinoma (including nasopharyngeal carcino…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.